WO2002094835A1 - Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- WO2002094835A1 WO2002094835A1 PCT/FR2002/001715 FR0201715W WO02094835A1 WO 2002094835 A1 WO2002094835 A1 WO 2002094835A1 FR 0201715 W FR0201715 W FR 0201715W WO 02094835 A1 WO02094835 A1 WO 02094835A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- branched
- linear
- group
- formula
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems
Definitions
- the present invention relates to new tricyclic derivatives of dihydro-quinolines, their process of preparation, the pharmaceutical compositions which contain them as well as their use as anticancer.
- the compounds of the invention in addition to the fact that they are new, exhibit very advantageous antitumor properties.
- R ⁇ a - ôb and R f e identical or different, each represents a hydrogen atom or a linear or branched (Ci-C 6 ) alkyl group
- - R ô represents a linear or branched (C ⁇ -C 6 ) alkyl group when R 10 represents a hydrogen atom and a group selected from hydrogen and alkyl (C-. -C 6) linear or branched when R 10 represents an alkyl group (Cl- Ce) linear or branched
- - X represents an oxygen or sulfur atom or an NRe c group in which R ôc represents a hydrogen atom or a linear or branched (Ci-C 6 ) alkyl group,
- - Ri represents a hydrogen atom or a group chosen from:
- R 7a and R 7 b identical or different, each represent an alkyl group (Ci-C 6 ) linear or branched, optionally substituted by a hydroxy or amino group (itself optionally substituted by one or two alkyl groups (Ci-Ce) linear or branched), or else R 7a and R form together with the nitrogen atom who wear them a nitrogen heterocycle),
- R a and R 7b identical or different, each represent a group linear or branched (Ci-C 6 ) alkyl, optionally substituted by a hydroxy or amino group (itself optionally substituted by one or two linear or branched (Ci-C 6 ) alkyl groups, or else R 7a and R 7b form together with the nitrogen atom which carries them a nitrogen heterocycle, - or OR 9 in which R 9 represents a hydrogen atom or an aryl, or alkyl (Ci-C 6 ) linear or branched group optionally substituted by a group of formula NR 7a R7b in which R 7a and R 7b , identical or different, each represent a linear or branched (Ci-C 6 ) alkyl group, optionally substituted by a group of formula NR 7a R7b in which R 7a and R 7b , identical or different, each represent a linear or branched (Ci-C 6 ) alkyl group, optionally substituted by a
- R 2 , R 3 , Ri and R 5 identical or different, each represent: - a hydrogen atom, - a halogen atom, - a linear or branched alkyl group (C ⁇ -C 6 ),
- m represents an integer such that 1 ⁇ m ⁇ 4, or R 2 with R 3 , or R with IL-., or with R 5 , form together with the carbon atoms which carry them a mono- or bicyclic group of 5 to 12 members, aromatic or non-aromatic, optionally containing 1 or 2 heteroatoms chosen from O, S and N, and optionally substituted by one or more atoms or groups, identical or different, chosen from halogen atoms and alkyl groups (C ⁇ -C 6 ) linear or branched, hydroxy, alkoxy (C ⁇ -C 6 ) linear or branched, polyhaloalkyl (C ⁇ -C 6 ) linear or branched, amino (optionally substituted by one or more alkyl groups (C ⁇ -C 6 ) linear or branched), nitro , linear or branched acyl (C ⁇ -C 6 ) or alkylenedioxy (C -.- C),
- Rio represents a hydrogen atom or a linear or branched (Ci-Ce) alkyl group
- Ar represents a linear or branched aryl, heteroaryl or arylalkyl (C ⁇ -C 6 ) group
- hydrochloric hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic acids, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, oxalic, methanesulfonic, benzenesulfonic, camphoric.
- aryl group is understood to mean phenyl, biphenylyl, naphthyl or tetrahydronaphthyl, each of these groups being optionally substituted by one or more atoms or groups, identical or different, chosen from halogen atoms and alkyl groups (C ⁇ -C 6 ) linear or branched, hydroxy, alkoxy (Ci-Ce) linear or branched, polyhaloalkyl (C ⁇ -C 6 ) linear or branched, amino (optionally substituted by one or more alkyl groups (C ⁇ -C 6 ) linear or branched), nitro , acyl (C ⁇ -C 6 ) linear or branched or alkylenedioxy (C ⁇ -C 2 ).
- heteroaryl group is meant a mono- or bicyclic aromatic group of
- heteroaryl may be optionally substituted by one or more atoms or groups, identical or different, chosen from halogen atoms and groups linear or branched (C ⁇ -C 6 ), hydroxy, linear or branched (C ⁇ -C 6 ), linear or branched polyhaloalkyl (C ⁇ -C 6 ) or amino (optionally substituted by one or more alkyl groups (C--) C 6 ) linear or branched).
- heteroaryl groups non-limiting mention may be made of thienyl, pyridyl, furyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, isoquinolyl and pyrimidinyl groups.
- nitrogen heterocycle is meant a saturated monocyclic group of 5 to 7 members containing one, two or three heteroatoms, one of these heteroatoms being the nitrogen atom, and the additional heteroatom (s) possibly present being chosen from the atoms oxygen, nitrogen or sulfur.
- the preferred nitrogen heterocycles are the pyrrolidinyl, piperidyl, morpholinyl or piperazinyl groups.
- aromatic or non-aromatic optionally containing 1 or 2 heteroatoms chosen from O, S and N
- An advantageous aspect of the invention relates to the compounds of formula (I) for which Rio represents a hydrogen atom.
- Another advantageous aspect of the invention relates to the compounds of formula (I) for which Rio represents a linear or branched alkyl group (C ⁇ -C 6 ).
- R 6a , Re, Re c and Re are as defined in formula (I).
- R 2 , R 3; R). and R 5 each represents a hydrogen atom or a linear or branched (Ci-Ce) alkyl or linear or branched alkoxy (C ⁇ -C 6 ) group, or alternatively R 2 and R 3; or R 3 and R, form together with the carbon atoms which carry them a mono- or bicyclic group of 5 to 12 members, aromatic or non-aromatic, optionally containing 1 or 2 heteroatoms chosen from O, S and N.
- R 3 and P form together, with the carbon atoms which carry them, a group of formula G 3 or G 4 as defined above, and those for which R and R 3 together form, with the carbon atoms which carry them, a phenylene group.
- An advantageous aspect of the invention relates to the compounds of formula (I) for which Ar represents an aryl group. Among these, very particularly preferred are those for which Ar represents an optionally substituted phenyl group.
- Another advantageous aspect of the invention relates to the compounds of formula (I) for which Ar represents a heteroaryl group.
- R * represents a hydrogen atom, a linear or branched (Ci-Ce) alkyl group or an arylalkyl group in which the alkyl part is (C ⁇ -C 6 ) linear or branched.
- the invention also extends to a process for preparing the compounds of formula (I) characterized in that a compound of formula (II) is reacted:
- R-, R 2 , R 3 , R 4 , R 5 , R 10 and Ar are as defined above,
- R ,, R 2 , R 3 , R 4 , R 5 , R 10 and Ar are as defined above, compounds of formula (la) or (Ib) which constitute all of the compounds of formula (I), which are purified, if necessary, according to a conventional purification technique, from which, if desired, they are separated optical isomers according to a conventional separation technique, and which, if desired, is converted into their addition salts with a pharmaceutically acceptable acid.
- the compounds of the present invention in addition to the fact that they are new, exhibit advantageous pharmacological properties. They have cytotoxic properties which make them useful in the treatment of cancers.
- the invention also extends to pharmaceutical compositions containing as active principle at least one compound of formula (I) with one or more inert excipients, not toxic and appropriate.
- pharmaceutical compositions according to the invention mention may be made more particularly of those which are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous), nasal administration, simple or coated tablets, sublingual tablets, capsules, tablets, suppositories, creams, ointments, dermal gels, injections, oral suspensions, etc.
- the useful dosage is adaptable according to the nature and severity of the condition, the route of administration as well as the age and weight of the patient and any associated treatments. This dosage varies from 0.5 mg to 2 g per 24 hours in one or more doses.
- the starting materials used are known products or prepared according to known preparatory methods.
- the expected product is obtained according to the process described in Example 1 from 3,4-methylenedioxy-aniline, from 5,5-dimethyl-tetrahydrofuran-2,4-dione (the preparation of which is described in Chem. Pharm. Bull. 1984, 32, 3724) and 3,4,5-trimethoxybenzaldehyde. Melting point:> 260 ° C.
- the expected product is obtained according to the process described in Example 1 from 3,4-methylenedioxy-aniline, from 5,5-dimethyl-2,2-dioxo [1,2] oxathiolan-4-one (including the preparation is described in Tetral edron 1997, 17795) and 3,4,5-trimethoxybenzaldehyde. Drop point: 270-280 ° C.
- the expected product is obtained according to the process described in Example 5 from 3,4-methylenedioxy-aniline, tetronic acid and 3,4,5-trimethoxybenzaldehyde.
- the expected product is obtained according to the process described in Example 5 from 1-naphthylamine, tetronic acid and 3,4,5-trimethoxybenzaldehyde.
- Stage A N-methyl-3-methox aniline A solution of 3-methoxyaniline (10 mmol) in formic acid (36 ml) is heated at reflux for 1 hour. After removal of the excess formic acid, the residue obtained is diluted in water, then extracted with dichloromethane. The combined organic phases are evaporated. The residue obtained is dissolved in ether, then aluminum and lithium hydride (42 mmol) is added at 10 ° C, in small portions. After 3 hours of stirring at room temperature, water and 10% sodium hydroxide are added and the mixture is filtered through celite. The filtrate is dried, evaporated and the residue obtained is purified by chromatography on silica using dichloromethane as eluent to yield the expected product in the form of an oil.
- the expected product is obtained according to the process described in Example 5, replacing, in stage A, N-benzyl-3,4-methylenedioxyaniline with the compound obtained in the preceding stage. Drop point: 198-200 ° C
- PoinJ_deJusjon > 260 ° C.
- Miçro ttiçdyse elementaire _ C% H% N% calculated 71.02 4.70 4.36 found 70.93 4.84 4.20
- EXAMPLE 10 9-Methyl-6,7-methylenedioxy-9- (3,4,5-trimethoxyphenyl) -4,9- dihydrofuro [3,4-b] quinoline-1 (3jH) -one
- the cells are distributed in microplates and exposed to cytotoxic compounds. The cells are then incubated for 2 days (L1210) or
- the compounds of the invention exhibit cytotoxicity in vitro.
- the compound of Example 5 has an IC 50 (concentration of cytotoxic agent which inhibits the proliferation of the treated cells by 50%) of 0.19 ⁇ M (L1210).
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK1602-2003A SK16022003A3 (sk) | 2001-05-23 | 2002-05-22 | Tricyklické dihydrochinolínové zlúčeniny, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú |
BR0209974-8A BR0209974A (pt) | 2001-05-23 | 2002-05-22 | Derivados tricìclicos de dihidro-quinoleìnas, o respectivo processo de preparação e as composições farmacêuticas que os contêm |
JP2002591508A JP2004535405A (ja) | 2001-05-23 | 2002-05-22 | 新しい三環式ジヒドロキノリン化合物、これらの製造方法及びこれらを含む医薬組成物 |
US10/477,258 US20040198981A1 (en) | 2001-05-23 | 2002-05-22 | Tricyclic dihydroquinoline derivatives,method for preparing same and pharmaceutical compositions containing same |
EP02740805A EP1389210A1 (fr) | 2001-05-23 | 2002-05-22 | Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
PL02364082A PL364082A1 (en) | 2001-05-23 | 2002-05-22 | Tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same |
MXPA03010599A MXPA03010599A (es) | 2001-05-23 | 2002-05-22 | Derivados tiriciclicos de dihidroquinolinas, metodo para prepararlos y composiciones farmaceuticas que los contienen. |
EA200301171A EA200301171A1 (ru) | 2001-05-23 | 2002-05-22 | Новые соединения трициклических дигидрохинолинов, способ их получения и фармацевтические композиции, содержащие их |
CA002448191A CA2448191A1 (fr) | 2001-05-23 | 2002-05-22 | Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
KR10-2003-7015306A KR20030097898A (ko) | 2001-05-23 | 2002-05-22 | 트리시클릭 디히드로퀴놀린 유도체, 이의 제조 방법 및이를 함유하는 약제 조성물 |
HU0400436A HUP0400436A2 (hu) | 2001-05-23 | 2002-05-22 | Új triciklusos dihidrokinolin-vegyületek, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények |
NO20035215A NO20035215L (no) | 2001-05-23 | 2003-11-24 | Tricykliske dihydrokinolinforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0106792A FR2825091B1 (fr) | 2001-05-23 | 2001-05-23 | Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR01/06792 | 2001-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002094835A1 true WO2002094835A1 (fr) | 2002-11-28 |
Family
ID=8863589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/001715 WO2002094835A1 (fr) | 2001-05-23 | 2002-05-22 | Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (18)
Country | Link |
---|---|
US (1) | US20040198981A1 (fr) |
EP (1) | EP1389210A1 (fr) |
JP (1) | JP2004535405A (fr) |
KR (1) | KR20030097898A (fr) |
CN (1) | CN1511158A (fr) |
AR (1) | AR033915A1 (fr) |
BR (1) | BR0209974A (fr) |
CA (1) | CA2448191A1 (fr) |
CZ (1) | CZ20033495A3 (fr) |
EA (1) | EA200301171A1 (fr) |
FR (1) | FR2825091B1 (fr) |
HU (1) | HUP0400436A2 (fr) |
MX (1) | MXPA03010599A (fr) |
NO (1) | NO20035215L (fr) |
PL (1) | PL364082A1 (fr) |
SK (1) | SK16022003A3 (fr) |
WO (1) | WO2002094835A1 (fr) |
ZA (1) | ZA200308629B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1746097A1 (fr) * | 2005-07-20 | 2007-01-24 | Aventis Pharma S.A. | Héterocyles à fusion1,4-dihydropyridineprocédé de préparation, utilisation et compositions de celles-ci |
US9783547B2 (en) | 2014-01-15 | 2017-10-10 | Centre National De La Recherche Scientifique (Cnrs) | Water soluble 4-azapodophyllotoxin analogs |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2649078B1 (fr) * | 2010-12-06 | 2016-07-27 | Council of Scientific & Industrial Research | Composés de 4-aza-2, 3-didéshydropodophyllotoxine et procédés de préparation de ceux-ci |
US11098052B2 (en) | 2016-03-02 | 2021-08-24 | Arizona Board Of Regents On Behalf Of Arizona State University | 4-azapodophylotoxins compounds |
CN111494374B (zh) * | 2020-06-12 | 2021-08-03 | 广东省微生物研究所(广东省微生物分析检测中心) | 香草木宁碱在制备破骨细胞分化抑制剂中的应用 |
WO2024015793A2 (fr) * | 2022-07-12 | 2024-01-18 | Oregon Health & Science University | Énantiomère de derivé d'azopodophyllotoxine su056 |
US11731980B1 (en) | 2023-03-22 | 2023-08-22 | King Faisal University | Furo[3,4-b]quinolone compounds as antibacterial agents |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1103554A1 (fr) * | 1999-11-24 | 2001-05-30 | Adir Et Compagnie | Dérivés de dihydrofuro-(3,4-b) quinoléin-1-ones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
-
2001
- 2001-05-23 FR FR0106792A patent/FR2825091B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-22 PL PL02364082A patent/PL364082A1/xx unknown
- 2002-05-22 BR BR0209974-8A patent/BR0209974A/pt not_active Application Discontinuation
- 2002-05-22 CN CNA028102746A patent/CN1511158A/zh active Pending
- 2002-05-22 WO PCT/FR2002/001715 patent/WO2002094835A1/fr not_active Application Discontinuation
- 2002-05-22 HU HU0400436A patent/HUP0400436A2/hu unknown
- 2002-05-22 SK SK1602-2003A patent/SK16022003A3/sk unknown
- 2002-05-22 EP EP02740805A patent/EP1389210A1/fr not_active Withdrawn
- 2002-05-22 KR KR10-2003-7015306A patent/KR20030097898A/ko not_active Application Discontinuation
- 2002-05-22 CA CA002448191A patent/CA2448191A1/fr not_active Abandoned
- 2002-05-22 JP JP2002591508A patent/JP2004535405A/ja not_active Withdrawn
- 2002-05-22 US US10/477,258 patent/US20040198981A1/en not_active Abandoned
- 2002-05-22 MX MXPA03010599A patent/MXPA03010599A/es unknown
- 2002-05-22 EA EA200301171A patent/EA200301171A1/ru unknown
- 2002-05-22 CZ CZ20033495A patent/CZ20033495A3/cs unknown
- 2002-05-23 AR ARP020101906A patent/AR033915A1/es not_active Application Discontinuation
-
2003
- 2003-11-05 ZA ZA200308629A patent/ZA200308629B/en unknown
- 2003-11-24 NO NO20035215A patent/NO20035215L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1103554A1 (fr) * | 1999-11-24 | 2001-05-30 | Adir Et Compagnie | Dérivés de dihydrofuro-(3,4-b) quinoléin-1-ones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
Non-Patent Citations (2)
Title |
---|
HITOTSUYANAGI, YUKIO ET AL: "4-Aza-2,3-dehydro-4-deoxypodophyllotoxins: simple Aza-podophyllotoxin analogues possessing potent cytotoxicity", BIOORG. MED. CHEM. LETT. (2000), 10(4), 315-317, XP004189922 * |
HITOTSUYANAGI, YUKIO ET AL: "Synthesis of (-)-4-aza-4-deoxypodophyllotoxin from (-)-podophyllotoxin", TETRAHEDRON LETT. (1999), 40(51), 9107-9110, XP004184816 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1746097A1 (fr) * | 2005-07-20 | 2007-01-24 | Aventis Pharma S.A. | Héterocyles à fusion1,4-dihydropyridineprocédé de préparation, utilisation et compositions de celles-ci |
WO2007012972A3 (fr) * | 2005-07-20 | 2007-04-05 | Aventis Pharma Sa | Heterocycles fusionnes de 1,4-dihydropyridine, procede pour preparer ceux-ci, utilisations et compositions les contenant |
JP2009501778A (ja) * | 2005-07-20 | 2009-01-22 | アバンテイス・フアルマ・エス・アー | 1,4−ジヒドロピリジン縮合ヘテロ環、これらの調製法、使用およびこれらを含有する組成物 |
US8163768B2 (en) | 2005-07-20 | 2012-04-24 | Aventis Pharma S.A.. | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |
EA016815B1 (ru) * | 2005-07-20 | 2012-07-30 | Авентис Фарма С.А. | 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции |
KR101286796B1 (ko) | 2005-07-20 | 2013-07-17 | 아벤티스 파마 소시에떼아노님 | 1,4-디히드로피리딘-융합된 헤테로사이클, 그의 제조 방법,용도 및 그를 함유하는 조성물 |
US9783547B2 (en) | 2014-01-15 | 2017-10-10 | Centre National De La Recherche Scientifique (Cnrs) | Water soluble 4-azapodophyllotoxin analogs |
Also Published As
Publication number | Publication date |
---|---|
CZ20033495A3 (en) | 2004-05-12 |
SK16022003A3 (sk) | 2004-05-04 |
PL364082A1 (en) | 2004-12-13 |
KR20030097898A (ko) | 2003-12-31 |
BR0209974A (pt) | 2004-04-06 |
HUP0400436A2 (hu) | 2004-09-28 |
NO20035215D0 (no) | 2003-11-24 |
ZA200308629B (en) | 2004-11-05 |
FR2825091A1 (fr) | 2002-11-29 |
AR033915A1 (es) | 2004-01-07 |
FR2825091B1 (fr) | 2003-07-04 |
NO20035215L (no) | 2003-11-24 |
MXPA03010599A (es) | 2004-03-09 |
US20040198981A1 (en) | 2004-10-07 |
EP1389210A1 (fr) | 2004-02-18 |
CN1511158A (zh) | 2004-07-07 |
CA2448191A1 (fr) | 2002-11-28 |
EA200301171A1 (ru) | 2004-04-29 |
JP2004535405A (ja) | 2004-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0995743A1 (fr) | Dérivés de dihydro- et tétrahydroquinoléine en tant qu'antioxydant médical | |
EP1103554B9 (fr) | Dérivés de dihydrofuro-(3,4-b) quinoléin-1-ones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
WO2002094835A1 (fr) | Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2696465A1 (fr) | Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
FR2801054A1 (fr) | Nouveaux derives de 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo [3,4-c]carbazole et 12,13-(pyranosyl)-furo[3,4-c]indolo [2,3-a]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1664055B1 (fr) | Derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1042326B1 (fr) | Nouveaux derives de l'acronycine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1590355A1 (fr) | Derives d azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1513833B1 (fr) | Nouveaux derives de 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinolein-4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2002094840A2 (fr) | Derives tricycliques de dihydroquinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1561753A2 (fr) | Dérivés de benzo[b]chroménonapthyridin-7-one et de pyrano[2',3':7,8]quino[2,3-b]quinoxalin-7-one, leur procédé de préparation, les compositions pharmaceutiques qui les contiennent et leurs propriétés antitumorales pour le traitement du cancer | |
EP1587810B1 (fr) | NOUVEAUX DERIVES DE 1,4 BENZODIOXINO 2,3-e ISOINDOLE SUBSTITUES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT | |
EP0982308B1 (fr) | Dérivés de 8H-(2,3-b)-pyrrolizine-8-one, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
FR2795071A1 (fr) | Nouveaux derives de carboxylate de 7-oxo-2,3,7,14- tetrahydro-1h-benzo[b]pyrano[3,2,h] acridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1556387B1 (fr) | Derives de benzo (e) (1,4) oxazino (3,2-g) isoindole substi tues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2826009A1 (fr) | Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2004069844A1 (fr) | Nouveaux derives d'oxazepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2879600A1 (fr) | Nouveaux derives cinnamates de benzo[b]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP0895995A1 (fr) | Nouveaux composés de bis [4,3-b]carbazole leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
FR2902792A1 (fr) | Nouveaux derives cinnamates de tetrahydro-7h-pyrano(2,3-c)acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2779725A1 (fr) | Nouveaux derives de 5,10-dihydrodipyrido[2,3-b:2,3-e] pyrazine et 5,10-dihydrodipyrido[2,3-b:3,2-e]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2892418A1 (fr) | Nouveaux composes aminoesterifies a cycle e hydrocarbone a six chainons analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2892417A1 (fr) | Nouveaux composes aminoesterifies a cycle e hydrocarbone a sept chainons analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003/08629 Country of ref document: ZA Ref document number: 200308629 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 529357 Country of ref document: NZ Ref document number: 2002740805 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10477258 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/010599 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028102746 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002314243 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037015306 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2448191 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002591508 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200301171 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-3495 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 16022003 Country of ref document: SK |
|
WWP | Wipo information: published in national office |
Ref document number: 2002740805 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-3495 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002740805 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2003-3495 Country of ref document: CZ |